Bio

Erin Grady, MD, CCD, FACNM, FSNMMI is a nuclear medicine physician at Stanford Hospital and Clinics in Stanford, California. She serves as the Interim Division Chief of Nuclear Medicine and Molecular Imaging, Associate Chair of Education, and is program director for the nuclear radiology and nuclear oncology fellowship programs, as well as a coach for the diagnostic radiology program. She is actively involved nationally in the Society of Nuclear Medicine and Molecular Imaging as a Director-at-Large on the SNMMI Board of Directors, and chair of the Government Relations Committee. She serves on the Nuclear Medicine Residency Review Committee for ACGME appeals panel member and assisted with milestone 1.0 development committee for Nuclear Medicine and 2.0 milestone revision committee for Nuclear Radiology at the ACGME. She has been involved in multiple guideline and appropriate use documents on topics related to thyroid cancer (NCCN panel), neuroendocrine tumors, bone scintigraphy, lung scintigraphy and more. In addition, she is a past chair of the American Board of Nuclear Medicine and past president of the American College of Nuclear Medicine. Her areas of research interest include quality, education, radiopharmaceutical therapy and finding answers to clinical questions that arise during the course of practice. She is passionate about education, nuclear medicine’s future, collaboration across specialties, and is a staunch advocate for patients.

Academic Appointments

Honors & Awards

  • Best Clinical Mentor, American College of Nuclear Medicine (2024)
  • Radiology Faculty of the Year, Stanford (2024)
  • Fellow, Society of Nuclear Medicine and Molecular Imaging (2023)
  • Distinguished Service Award, Academic Council of the Society of Nuclear Medicine and Molecular Imaging (2022)
  • Rising Star, Emory Department of Radiology and Imaging Sciences (2020)
  • Fellow, American College of Nuclear Medicine (2015)
  • Rising Star Award, Christiana Care Health System (2015)
  • Robert E. Henkin Government Relations Fellowship, Society of Nuclear Medicine and Molecular Imaging (2012)

Boards, Advisory Committees, Professional Organizations

  • Panel Member - Thyroid Cancer, National Comprehensive Cancer Network (2023 - Present)
  • Board of Directors Member, Intersocietal Accreditation Commission (Nuclear/PET; Therapy) (2021 - Present)
  • Director at Large, Society of Nuclear Medicine and Molecular Imaging (2021 - Present)
  • Board of Directors Member, Education and Research Foundation for Nuclear Medicine and Molecular Imaging (2018 - 2021)
  • Director, Exam Chair, Vice Chair, Chair, Past Chair, American Board of Nuclear Medicine (2014 - 2020)
  • Associate Editor of e-learning for Nuclear Medicine, Vice Chair Nuclear Medicine Radiology Assessment & Review-2, American College of Radiology (2013 - 2016)
  • Director, Newsletter Editor, Annual Meeting Program Chair, Treasurer, Secretary, Vice President Elect, Vice President, President, Past President, American College of Nuclear Medicine (2011 - 2021)

Professional Education

  • MD, University of Washington, School of Medicine, Medicine (2007)

Clinical Trials

  • Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers Not Recruiting

    The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

    Stanford is currently not accepting patients for this trial.

    View full details

All Publications

  • Executive Summary: SNMMI/EANM/ACNM/ANZSNM Procedure Standard/Procedure Guideline for Ventilation-Perfusion Pulmonary Scintigraphy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine Roach, P. J., Bailey, D. L., Currie, G. M., Grady, E. E., Haramati, L. B., LeBlanc, M., Lee, A. C., Le Roux, P. Y., Metter, D. F., Salaun, P. Y., Siegel, B. A. 2026

    View details for DOI 10.2967/jnumed.126.273689

    View details for PubMedID 42754348

  • Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [177Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine Park, H. L., Kersting, D., Bergstrom, C. P., Khaki, A. R., Shah, J., Davidzon, G. A., Moradi, F., Fan, A., Shah, S. A., Grady, E., Srinivas, S., Iagaru, A., Song, H. 2026

    Abstract

    This article evaluates whether early same-day posttherapy whole-body SPECT/CT assessed using visual RECIP 1.0 is associated with overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) that is positive for prostate-specific membrane antigen (PSMA) and treated with [177Lu]Lu-PSMA-617, and it assesses concordance among posttherapy SPECT/CT, PSMA PET/CT, and prostate-specific antigen (PSA). Methods: We retrospectively analyzed 158 men with mCRPC who received at least 2 cycles [177Lu]Lu-PSMA-617 between June 2022 and January 2025. Same-day posttherapy SPECT/CT was performed after each cycle. Early SPECT imaging response was assessed after cycle 2 using visual RECIP 1.0. Baseline tumor burden was classified as low or high volume using CHAARTED criteria on baseline SPECT. Early biochemical response was defined as a PSA decline of at least 50% (PSA50) before cycle 3. OS was the primary endpoint. Kaplan-Meier analysis, log-rank testing, and univariable and multivariable Cox regression were performed. Interim imaging response and concordance were evaluated for SPECT/CT and PSMA PET/CT after cycle 3. Results: Median follow-up was 23.9 mo, and median OS was 14.4 mo. Early SPECT response after cycle 2 was associated with longer OS than occurred with no response (21.5 vs. 11.3 mo, P < 0.001). High-volume baseline disease and absence of PSA50 were associated with shorter OS. The combination of imaging response, baseline tumor burden, and PSA50 improved survival stratification. Patients with high-volume disease and without imaging response were associated with the shortest OS compared with those with low-volume disease and imaging response (10.6 vs. 23.7 mo, P < 0.001). Among patients who underwent interim SPECT/CT and PSMA PET/CT (n = 97), progressive disease on either modality was associated with shorter survival. SPECT, PET, and PSA responses were concordant in 59.8% of patients. Discordant findings reflected differences in imaging timing, sensitivity, and biologic heterogeneity, including PSMA-negative disease. Conclusion: Early same-day posttherapy SPECT/CT assessed using visual RECIP 1.0 was associated with OS in patients with mCRPC who received [177Lu]Lu-PSMA-617. Integration of early SPECT response, baseline tumor burden, and PSA50 improved survival stratification. Substantial concordance among SPECT, PSMA PET, and PSA response, together with characteristic discordance patterns, supports a complementary role for SPECT/CT in treatment response assessment.

    View details for DOI 10.2967/jnumed.126.272651

    View details for PubMedID 42595491

  • Robert E. Henkin, MD, FACNM, FACR (1942-2026): Leader, Educator, Advocate, Friend, and Mentor. Journal of nuclear medicine : official publication, Society of Nuclear Medicine Grady, E. 2026

    View details for DOI 10.2967/jnumed.126.273025

    View details for PubMedID 42242870

  • Adverse Events in Targeted Radionuclide Therapy. Radiographics : a review publication of the Radiological Society of North America, Inc Guja, K. E., Wu, J., Agordzo, H. L., Kwofie, J., Samaan, D., Nadel, H. R., Grady, E., Shah, J. 2025; 45 (9): e240143

    Abstract

    Targeted radionuclide therapy (TRT) plays an important role in management of oncology patients, particularly those with thyroid cancer, prostate cancer, or neuroendocrine tumor. Use of TRTs has expanded rapidly in recent years, with approval of new agents and indications. The number of ongoing TRT clinical trials suggests that this trend is likely to continue in the future. Adequate knowledge of potential adverse events and their management is essential for treating physicians to optimize outcomes in patients undergoing TRT. The authors review adverse events that may occur in TRT; their clinical manifestations, incidence, risk factors, and management; and strategies to prevent or decrease their risk of occurrence. ©RSNA, 2025.

    View details for DOI 10.1148/rg.240143

    View details for PubMedID 40839540

  • Thyroid Carcinoma, Version 1.2025 Featured Updates to the NCCN Guidelines® JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Haddad, R. I., Bischoff, L., Applewhite, M., Bernet, V., Blomain, E., Brito, M., Busaidy, N., Campbell, M., Delozier, O., Duh, Q., Ehya, H., Grady, E., Guo, T., Haymart, M., Hunt, J. P., Kandeel, F., Kotwal, A., Lamonica, D. M., Lorch, J., Mandel, S. J., Markovina, S., Mydlarz, W., Nabell, L., Raeburn, C. D., Rezaee, R., Ridge, J. A., Ritter, H., Roth, M. Y., Salgado, S., Scheri, R. P., Shah, J. P., Sipos, J. A., Sippel, R., Sturgeon, C., Wirth, L. J., Wong, R. J., Worden, F., Yeh, M. W., Darlow, S., Cassara, C. J., Sliker, B. 2025; 23 (7)

    View details for DOI 10.6004/jnccn.2025.0033

    View details for Web of Science ID 001531424600017

    View details for PubMedID 40639400

  • Evaluation of Patients with Suspected Parathyroid Adenoma and Negative or Equivocal Tc99m-Sestamibi SPECT/CT Using F18-Fluorocholine PET/CT: Preliminary Results Guja, K., Patel, H., Kebebew, E., Cisco, R., Lin, D., Grady, E., Shah, J., Moradi, F., Song, H., Iagaru, A. SOC NUCLEAR MEDICINE INC. 2025

    View details for Web of Science ID 001549925200005

  • The SNMMI/ACNM Practice Guideline for the Use of Radiopharmaceuticals 5.0 JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY Weatherman, K., Grady, E., Mastascusa, N., Johnson, S., Hinkle, G. H., Laforest, R., Wendorf, C., Thomas, K. S. 2025; 53 (2): 130-134

    View details for Web of Science ID 001509143500008

    View details for PubMedID 40169271

  • Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO oncology practice Perez, K., Del Rivero, J., Kennedy, E. B., Basu, S., Chauhan, A., Connolly, H. M., Dasari, A. N., Gangi, A., Clarke, C. N., Hallet, J., Howe, J. R., Grady, E., Ivanidze, J., Mittra, E. S., White, S. B., Raj, N. P., Vijayvergia, N., Lewis, M. A., Chan, J. A., Kunz, P. L., Mailman, J., Arshad, J., Soares, H. P., Singh, S., Chandrasekharan, C., Soulen, M. C., Janson, E. T., Halfdanarson, T. R., Strosberg, J. R., Bergsland, E. K. 2025: OP2500133

    Abstract

    PURPOSE: To develop a clinical practice guideline and recommendations for symptom management of patients with well-differentiated grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors.METHODS: ASCO convened an Expert Panel to develop a clinical practice guideline by reviewing the literature for relevant guidelines, systematic reviews, randomized controlled trials (RCTs), and observational studies to develop recommendations for clinical practice.RESULTS: The literature review identified eight guidelines, 19 systematic reviews, and three RCTs that informed the development of guideline recommendations.RECOMMENDATIONS: Recommendations are included for carcinoid syndrome, carcinoid heart disease and carcinoid crisis, and functional pancreatic neuroendocrine tumor syndromes. Recommendations are provided for surgical management, liver-directed therapy, and systemic therapy options, as well as palliative care. Limited guidance is provided for sequencing of interventions.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.

    View details for DOI 10.1200/OP-25-00133

    View details for PubMedID 40344544

  • The SNMMI/ACNM Practice Guideline for the Use of Radiopharmaceuticals 5.0. Journal of nuclear medicine technology Weatherman, K., Grady, E. E., Mastascusa, N., Johnson, S., Hinkle, G. H., Laforest, R., Wendorf, C., Thomas, K. S. 2025

    View details for DOI 10.2967/jnmt.125.269834

    View details for PubMedID 40169271

  • The Global Reading Room: Performing a Ventilation-Perfusion Study in a Patient With Recent COVID-19. AJR. American journal of roentgenology Grady, E., Pattison, D. A., Redman, S., Satoh, Y. 2024

    View details for DOI 10.2214/AJR.24.31348

    View details for PubMedID 38691414

  • Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology Del Rivero, J., Perez, K., Kennedy, E. B., Mittra, E. S., Vijayvergia, N., Arshad, J., Basu, S., Chauhan, A., Dasari, A. N., Bellizzi, A. M., Gangi, A., Grady, E., Howe, J. R., Ivanidze, J., Lewis, M., Mailman, J., Raj, N., Soares, H. P., Soulen, M. C., White, S. B., Chan, J. A., Kunz, P. L., Singh, S., Halfdanarson, T. R., Strosberg, J. R., Bergsland, E. K. 2023: JCO2301529

    Abstract

    PURPOSE: To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.RESULTS: Eight randomized controlled trials met the inclusion criteria for the systematic review.RECOMMENDATIONS: Somatostatin analogs (SSAs) are recommended as first-line systemic therapy for most patients with G1-grade 2 (G2) metastatic well-differentiated GI-NETs. Observation is an option for patients with low-volume or slow-growing disease without symptoms. After progression on SSAs, peptide receptor radionuclide therapy (PRRT) is recommended as systematic therapy for patients with somatostatin receptor (SSTR)-positive tumors. Everolimus is an alternative second-line therapy, particularly in nonfunctioning NETs and patients with SSTR-negative tumors. SSAs are standard first-line therapy for SSTR-positive pancreatic (pan)NETs. Rarely, observation may be appropriate for asymptomatic patients until progression. Second-line systemic options for panNETs include PRRT (for SSTR-positive tumors), cytotoxic chemotherapy, everolimus, or sunitinib. For SSTR-negative tumors, first-line therapy options are chemotherapy, everolimus, or sunitinib. There are insufficient data to recommend particular sequencing of therapies. Patients with G1-G2 high-volume disease, relatively high Ki-67 index, and/or symptoms related to tumor growth may benefit from early cytotoxic chemotherapy. For G3 GEP-NETs, systemic options for G1-G2 may be considered, although cytotoxic chemotherapy is likely the most effective option for patients with tumor-related symptoms, and SSAs are relatively ineffective. Qualifying statements are provided to assist with treatment choice. Multidisciplinary team management is recommended, along with shared decision making with patients, incorporating their values and preferences, potential benefits and harms, and other characteristics and circumstances, such as comorbidities, performance status, geographic location, and access to care.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.

    View details for DOI 10.1200/JCO.23.01529

    View details for PubMedID 37774329

  • Stronger Together-Collaboration Will Only Enhance Patient Care. Journal of nuclear medicine : official publication, Society of Nuclear Medicine Grady, E. E., Mankoff, D. A., Schuster, D. M. 2023

    View details for DOI 10.2967/jnumed.123.265673

    View details for PubMedID 37562806

  • A Case-Based Primer on FDG PET/CT for Imaging Cardiovascular Infections: Protocol, Interpretation, and Pitfalls. Zhou, W., Moradi, F., Davidzon, G., Song, H., Grady, E., Nguyen, J., Franc, B., Aparici, C., Iagaru, A., Shah, J. SOC NUCLEAR MEDICINE INC. 2023

    View details for Web of Science ID 001109210201036

  • Nuts and Bolts of Ra-223-Dichloride Therapy JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY Grady, E. 2022; 50 (3): 215-221

    Abstract

    Radionuclide therapy with 223Ra-dichloride can be helpful for patients with osteoblastic osseous metastatic disease in the setting of castration resistant prostate cancer without visceral metastases. This article reviews the indications, proper use and handling, patient work-up prior to therapy and many of the technical considerations including discussion of coding/billing along with pitfalls that have been identified.

    View details for DOI 10.2967/jnmt.122.263812

    View details for Web of Science ID 000892612400006

    View details for PubMedID 35882585